HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Warns Ayurvedic UMA Oils Brand For Claims Slip-Ups

This article was originally published in The Rose Sheet

Executive Summary

UMA Oils must lose claims on its skin- and hair-care products regarding acne and eczema treatment, among others, if it intends to continue marketing them as cosmetics, FDA says in a July warning letter. The company touts its offerings as based on ancient Ayurvedic principles and five generations of family expertise.

You may also be interested in...



FDA Warning Letter Prompts Be Natural Organics To Revise Web Claims

The agency highlights claims for nine Be Natural Organics products – including statements about collagen production, cellular regeneration, hyperpigmentation reduction and eczema and acne treatment – in its recent warning letter to the company.

FDA's Online Surveillance Continues With Warning Letter To Blissoma

Blissoma Holistic Skincare and Apothecary draws an FDA warning for verboten claims on its Flawless Equalizing Anti-Blemish Oil Serum and Lavish Loving Recovery Beta-Glucan Mask, among other offerings.

‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions

Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.

Topics

UsernamePublicRestriction

Register

RS121115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel